$ABBV Recent News Gilead shares up 3% as Morga
Post# of 88934
Posted On: 12/31/2014 10:06:16 AM
$ABBV Recent News
Gilead shares up 3% as Morgan Stanley upgrades to overweight 10:07 a.m. Dec. 29, 2014 - Ciara Linnane
AbbVie's stock rallies 1.8%, leads S&P 500 gainers 9:34 a.m. Dec. 24, 2014 - Tomi Kilgore
Health-care sector taking a broad beating as pricing fears grow 2:39 p.m. Dec. 23, 2014 - Tomi Kilgore
Steelcase shares slide as revenue comes in light 5:42 p.m. Dec. 22, 2014 - MarketWatch
S&P 500, Dow industrials close at records 4:41 p.m. Dec. 22, 2014 - Sara Sjolin
Stock market may wish investors a wary Christmas 8:19 a.m. Dec. 22, 2014 - Shawn Langlois
Express Scripts picks AbbVie over Gilead for hepatitis C drug 7:45 a.m. Dec. 22, 2014 - Joseph Walker
FDA approves AbbVie’s hepatitis treatment 3:33 p.m. Dec. 19, 2014 - Peter Loftus
AbbVie's stock gains 0.8% after FDA approval of hepatitis C treatment 3:21 p.m. Dec. 19, 2014 - Tomi Kilgore
Which stocks the billionaires are buying — and selling 1:32 p.m. Dec. 12, 2014 - The Trading Deck
Paulson takes stake in Abbvie, adds to Shire holdings 6:46 p.m. Nov. 14, 2014 - MarketWatch
Obama considering Lazard banker for Treasury post 4:20 p.m. Nov. 12, 2014 - Victoria McGrane
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Merck, Dendreon miss out on health-care rally 12:39 p.m. Nov. 10, 2014 - Russ Britt
S&P 500, Dow close at record levels 4:16 p.m. Oct. 31, 2014 - Barbara Kollmeyer
Apple rallies to record high; LinkedIn jumps 11:05 a.m. Oct. 31, 2014 - Sue Chang
AbbVie stock up 3.6% at $63.38 9:32 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie shares up 4% in premarket trade 8:52 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie raises outlook as profit, sales beat 8:26 a.m. Oct. 31, 2014 - MarketWatch.com
AbbVie shares up 2% as profit, sales beat estimates 8:00 a.m. Oct. 31, 2014 - Ciara Linnane
RBC provides commentary on Viekira Pak ramp up 8:12 a.m. Today - Seeking Alpha
Repros Gains on Positive Updates on the Status of Androxal - Analyst Blog 5:20 p.m. Dec. 30, 2014 - Zacks.com
Events That Shaped a Turbulent 2014 5:12 p.m. Dec. 30, 2014 - The Wall Street Journal Interactive Edition
Year of Highs and Lows for Hedge Funds 3:45 p.m. Dec. 30, 2014 - The Wall Street Journal Interactive Edition
Roche's Ebola Test Gets FDA's Emergency Use Authorization - Analyst Blog 3:40 p.m. Dec. 30, 2014 - Zacks.com
Hedge Funds Stumble Over M&A in 2014 3:16 p.m. Dec. 30, 2014 - The Wall Street Journal Interactive Edition
Coherus Biosciences: The Biosimilar Market Is Enormous And This Company Is Well Positioned 3:08 p.m. Dec. 30, 2014 - Seeking Alpha
Gilead Long-Term Prognosis Is Promising 2:10 p.m. Dec. 30, 2014 - Seeking Alpha
3 Biotech Stocks That Soared Past Gilead in 2014 - Analyst Blog 10:41 a.m. Dec. 30, 2014 - Zacks.com
Gilead Stock: This Beatdown Was Way Overdone (GILD) 5:42 a.m. Dec. 30, 2014 - InvestorPlace.com
U.S. M&A Seen Staying Robust In 2015, Fueled By Oil 5:38 p.m. Dec. 29, 2014 - Investors Business Daily
Novartis' Cosentyx Approved in Japan for Psoriatic Arthritis - Analyst Blog 4:20 p.m. Dec. 29, 2014 - Zacks.com
Barron’s 10 Favorite Stocks for 2015 4:19 p.m. Dec. 29, 2014 - Barrons.com
S&P 500 Tiptoes to New High as Oil Selloff Fails to Stop Record Run 4:10 p.m. Dec. 29, 2014 - TheStreet.com
Stocks Hold Ground Against Crude Oil's Fresh Five-Year Lows 3:06 p.m. Dec. 29, 2014 - TheStreet.com
Gilead Sciences: After The Bloodbath The Stock Is A Strong Buy 2:52 p.m. Dec. 29, 2014 - Seeking Alpha
Gilead Sciences Seen Benefiting From Hep C Market 2:34 p.m. Dec. 29, 2014 - Investors Business Daily
Is it Time to Sell Gilead Sciences? 2:05 p.m. Dec. 29, 2014 - GuruFocus.com
Is Gilead Already Coming Back Into Favor? 10:08 a.m. Dec. 29, 2014 - 247WallSt.com
Corrections Are Coming in 2015 5:30 a.m. Dec. 29, 2014 - InvestorPlace.com
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
AbbVie to Present at Goldman Sachs Healthcare CEOs Unscripted Conference 8:00 a.m. Dec. 23, 2014 - PR Newswire - PRF
Pharma Deals Watch: Coverage Initiated on AstraZeneca, Advaxis, Radius Health, Cubist and AbbVie 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
Express Scripts and AbbVie Make Hepatitis C Cure Available to Millions of Patients in Need 7:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines 9:10 a.m. Dec. 12, 2014 - PR Newswire - PRF
AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting 8:15 p.m. Dec. 7, 2014 - PR Newswire - PRF
Gardy & Notis LLP Issues Notice Of The Filing Of A Securities Class Action Against AbbVie And Its Chief Executive Officer 4:00 p.m. Nov. 26, 2014 - PR Newswire - PRF
CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe 8:00 a.m. Nov. 21, 2014 - PR Newswire - PRF
AbbVie to Present at Jefferies 2014 Global Healthcare Conference 7:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 4:48 p.m. Nov. 14, 2014 - PR Newswire - PRF
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014 9:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014 8:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
Infinity Reports Third Quarter 2014 Financial Results and Provides Company Update 4:01 p.m. Nov. 6, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
ABBVIE (ABBV) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty 8:03 a.m. Nov. 5, 2014 - BusinessWire - BZX
AbbVie to Present at Credit Suisse 2014 Healthcare Conference 8:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
ABBVIE INC. ALERT -- Andrews & Springer LLC is Investigating AbbVie Inc. for Potential Securities Fraud and Breach of Fiduciary Duty 8:09 a.m. Nov. 3, 2014 - GlobeNewswire
Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM) 7:05 a.m. Nov. 3, 2014 - GlobeNewswire
CMK Select Recognized as Women's Business Enterprise 10:45 a.m. Oct. 31, 2014 - Marketwired
AbbVie Reports Third-Quarter 2014 Financial Results 7:49 a.m. Oct. 31, 2014 - PR Newswire - PRF
Gilead shares up 3% as Morgan Stanley upgrades to overweight 10:07 a.m. Dec. 29, 2014 - Ciara Linnane
AbbVie's stock rallies 1.8%, leads S&P 500 gainers 9:34 a.m. Dec. 24, 2014 - Tomi Kilgore
Health-care sector taking a broad beating as pricing fears grow 2:39 p.m. Dec. 23, 2014 - Tomi Kilgore
Steelcase shares slide as revenue comes in light 5:42 p.m. Dec. 22, 2014 - MarketWatch
S&P 500, Dow industrials close at records 4:41 p.m. Dec. 22, 2014 - Sara Sjolin
Stock market may wish investors a wary Christmas 8:19 a.m. Dec. 22, 2014 - Shawn Langlois
Express Scripts picks AbbVie over Gilead for hepatitis C drug 7:45 a.m. Dec. 22, 2014 - Joseph Walker
FDA approves AbbVie’s hepatitis treatment 3:33 p.m. Dec. 19, 2014 - Peter Loftus
AbbVie's stock gains 0.8% after FDA approval of hepatitis C treatment 3:21 p.m. Dec. 19, 2014 - Tomi Kilgore
Which stocks the billionaires are buying — and selling 1:32 p.m. Dec. 12, 2014 - The Trading Deck
Paulson takes stake in Abbvie, adds to Shire holdings 6:46 p.m. Nov. 14, 2014 - MarketWatch
Obama considering Lazard banker for Treasury post 4:20 p.m. Nov. 12, 2014 - Victoria McGrane
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Merck, Dendreon miss out on health-care rally 12:39 p.m. Nov. 10, 2014 - Russ Britt
S&P 500, Dow close at record levels 4:16 p.m. Oct. 31, 2014 - Barbara Kollmeyer
Apple rallies to record high; LinkedIn jumps 11:05 a.m. Oct. 31, 2014 - Sue Chang
AbbVie stock up 3.6% at $63.38 9:32 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie shares up 4% in premarket trade 8:52 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie raises outlook as profit, sales beat 8:26 a.m. Oct. 31, 2014 - MarketWatch.com
AbbVie shares up 2% as profit, sales beat estimates 8:00 a.m. Oct. 31, 2014 - Ciara Linnane
RBC provides commentary on Viekira Pak ramp up 8:12 a.m. Today - Seeking Alpha
Repros Gains on Positive Updates on the Status of Androxal - Analyst Blog 5:20 p.m. Dec. 30, 2014 - Zacks.com
Events That Shaped a Turbulent 2014 5:12 p.m. Dec. 30, 2014 - The Wall Street Journal Interactive Edition
Year of Highs and Lows for Hedge Funds 3:45 p.m. Dec. 30, 2014 - The Wall Street Journal Interactive Edition
Roche's Ebola Test Gets FDA's Emergency Use Authorization - Analyst Blog 3:40 p.m. Dec. 30, 2014 - Zacks.com
Hedge Funds Stumble Over M&A in 2014 3:16 p.m. Dec. 30, 2014 - The Wall Street Journal Interactive Edition
Coherus Biosciences: The Biosimilar Market Is Enormous And This Company Is Well Positioned 3:08 p.m. Dec. 30, 2014 - Seeking Alpha
Gilead Long-Term Prognosis Is Promising 2:10 p.m. Dec. 30, 2014 - Seeking Alpha
3 Biotech Stocks That Soared Past Gilead in 2014 - Analyst Blog 10:41 a.m. Dec. 30, 2014 - Zacks.com
Gilead Stock: This Beatdown Was Way Overdone (GILD) 5:42 a.m. Dec. 30, 2014 - InvestorPlace.com
U.S. M&A Seen Staying Robust In 2015, Fueled By Oil 5:38 p.m. Dec. 29, 2014 - Investors Business Daily
Novartis' Cosentyx Approved in Japan for Psoriatic Arthritis - Analyst Blog 4:20 p.m. Dec. 29, 2014 - Zacks.com
Barron’s 10 Favorite Stocks for 2015 4:19 p.m. Dec. 29, 2014 - Barrons.com
S&P 500 Tiptoes to New High as Oil Selloff Fails to Stop Record Run 4:10 p.m. Dec. 29, 2014 - TheStreet.com
Stocks Hold Ground Against Crude Oil's Fresh Five-Year Lows 3:06 p.m. Dec. 29, 2014 - TheStreet.com
Gilead Sciences: After The Bloodbath The Stock Is A Strong Buy 2:52 p.m. Dec. 29, 2014 - Seeking Alpha
Gilead Sciences Seen Benefiting From Hep C Market 2:34 p.m. Dec. 29, 2014 - Investors Business Daily
Is it Time to Sell Gilead Sciences? 2:05 p.m. Dec. 29, 2014 - GuruFocus.com
Is Gilead Already Coming Back Into Favor? 10:08 a.m. Dec. 29, 2014 - 247WallSt.com
Corrections Are Coming in 2015 5:30 a.m. Dec. 29, 2014 - InvestorPlace.com
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
AbbVie to Present at Goldman Sachs Healthcare CEOs Unscripted Conference 8:00 a.m. Dec. 23, 2014 - PR Newswire - PRF
Pharma Deals Watch: Coverage Initiated on AstraZeneca, Advaxis, Radius Health, Cubist and AbbVie 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
Express Scripts and AbbVie Make Hepatitis C Cure Available to Millions of Patients in Need 7:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines 9:10 a.m. Dec. 12, 2014 - PR Newswire - PRF
AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting 8:15 p.m. Dec. 7, 2014 - PR Newswire - PRF
Gardy & Notis LLP Issues Notice Of The Filing Of A Securities Class Action Against AbbVie And Its Chief Executive Officer 4:00 p.m. Nov. 26, 2014 - PR Newswire - PRF
CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe 8:00 a.m. Nov. 21, 2014 - PR Newswire - PRF
AbbVie to Present at Jefferies 2014 Global Healthcare Conference 7:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 4:48 p.m. Nov. 14, 2014 - PR Newswire - PRF
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014 9:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014 8:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
Infinity Reports Third Quarter 2014 Financial Results and Provides Company Update 4:01 p.m. Nov. 6, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
ABBVIE (ABBV) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty 8:03 a.m. Nov. 5, 2014 - BusinessWire - BZX
AbbVie to Present at Credit Suisse 2014 Healthcare Conference 8:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
ABBVIE INC. ALERT -- Andrews & Springer LLC is Investigating AbbVie Inc. for Potential Securities Fraud and Breach of Fiduciary Duty 8:09 a.m. Nov. 3, 2014 - GlobeNewswire
Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM) 7:05 a.m. Nov. 3, 2014 - GlobeNewswire
CMK Select Recognized as Women's Business Enterprise 10:45 a.m. Oct. 31, 2014 - Marketwired
AbbVie Reports Third-Quarter 2014 Financial Results 7:49 a.m. Oct. 31, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼